Clinical Trials Directory

Fulvestrant in Hormone-refractory Prostate Cancer

The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have a rising serum prostate specific antigen (PSA).

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Fulvestrant

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Must give signed written informed consent - Must be of age 18 years or older - Histologically confirmed adenocarcinoma of the prostate - Must be currently receiving LHRH agonists and have castrate levels of testosterone or have had an orchiectomy - Must have had rise in PSA despite anti-androgen withdrawal - Must exhibit two consecutive rises in PSA after the last hormonal manipulation - Minimum PSA > 5mg/dL - KPS > 80% - Up to one prior chemotherapy treatments allowed - Life expectancy of greater than 6 months

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
Not Recruiting

Footer Links: